XBiotech Wins “Commercial Real Estate Award for Industrial Development” for its Headquarters in Austin, Texas
June 26 2019 - 8:30AM
XBiotech Wins “Commercial Real Estate Award for Industrial
Development” for its Headquarters in Austin, Texas
XBiotech Inc. (NASDAQ: XBIT) announced today that it is the
recipient of the first place 2019 Commercial Real Estate Award for
Industrial Development, chosen by the Austin Business Journal.
XBiotech USA Inc. received the award for its integrated R&D,
administrative, and manufacturing facility located just 15 minutes
from downtown Austin. XBiotech began construction of its
state-of-the-art facility in 2015 as part of a master plan to build
its worldwide operations headquarters.
The Austin Business Journal reported, “a ‘green
living’ concept served as the guiding vision of the Southeast
Austin campus of biosciences company XBiotech USA Inc.
The 40,000-square-foot facility was built on 48 acres of dense
terrain including creeks, dense vegetations…and a 100-year flood
plain running across the south end of the site.”
Austin's Best New Buildings: XBiotech
Named as Winner in 2019 Commercial Real Estate Awards
The acclaimed “open air” facility is home to
XBiotech’s proprietary True Human™ therapeutic antibody discovery
and manufacturing platform. True Human™ antibodies are not
commercially produced or marketed anywhere else in the world (all
currently available/marketed therapeutic antibodies are either of
animal origin or have been modified from the original human
sequences in attempt to target specific diseases. Modified
antibodies differ from antibodies that the human body
creates*). XBiotech produces the only therapeutic antibodies
in clinical development that are derived from the natural human
immune response, including the Company’s lead anti-inflammatory
antibody, bermekimab. The unique discovery and manufacturing
processes undertaken at XBiotech’s Austin location distinguishes
the Company and its products from all other pharmaceutical
developers.
*Currently marketed biologic antibody treatments
are classified as either “Humanized” or “Fully Human”.
“Humanized” antibodies have been sourced from non-human species and
modified to become more similar to human antibodies.
https://en.wikipedia.org/wiki/Humanized_antibody “Fully Human”
antibodies are derived from either transgenic mice or developed
from human gene sequences that are modified to create antibody
drug. When either “Humanized” or so-called “Fully Human”
antibodies are introduced into the human bloodstream, the immune
system can recognize this as foreign and react to reject them, and
these antibodies can cause various side effects.
https://en.wikipedia.org/wiki/Monoclonal_antibody
XBiotech’s True Human™ antibodies are sourced
from humans and derived without modification from individuals who
possess natural immunity to certain diseases. With discovery and
clinical programs across multiple disease areas, XBiotech’s True
Human™ antibodies have the potential to harness the body’s natural
immunity to fight disease with a high degree of safety, efficacy,
and tolerability.
At its Austin location, XBiotech uses its
proprietary Super High Stringency Antibody Mining (SHSAM™)
technology to screen hundreds to thousands of human blood donations
to identify the most medically important antibodies from
individuals naturally immune to specific diseases. After the
desired antibodies are identified from an individual, the genes
responsible for producing those antibodies are identified. Those
genes are copied for production in a unique and scalable mammalian
expression system that involves the use of bioreactor technology
designed and engineered by XBiotech.
XBiotech’s state-of-the-art bioreactor
technology replaces the complex, extremely expensive plant and
equipment infrastructure that is used by other producers of
antibody therapeutics. This technology allows XBiotech to produce
antibodies on a commercial scale at a fraction of the capital cost,
and at a fraction of the lead time than typically required in the
pharmaceutical industry.
John Simard, Chairman & CEO of XBiotech,
commented, “We are very proud of our people and our infrastructure.
The facility was designed and built around a vision to assimilate
our operations into the beautiful surrounding hill country, sparing
trees and the natural ecosystem as much as possible to create a
serene, even rejuvenating, work environment. The master plan for
the campus envisions as many as six buildings and 267,000 square
feet of administrative, research and development, and manufacturing
space. We are grateful to the Austin Business Journal and the City
of Austin for their support and recognition of our important
project.”
About XBiotech
XBiotech is a fully integrated global biosciences company
dedicated to pioneering the discovery, development and
commercialization of therapeutic antibodies based on its True
Human™ proprietary technology. XBiotech currently is
advancing a robust pipeline of antibody therapies to redefine the
standards of care in oncology, inflammatory conditions and
infectious diseases. Headquartered in Austin,
Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more
rapidly, cost-effectively and flexibly produce new therapies
urgently needed by patients worldwide. For more information,
visit www.xbiotech.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements, including declarations regarding management's beliefs
and expectations that involve substantial risks and uncertainties.
In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should," "would," "could,"
"expects," "plans," "contemplate," "anticipates," "believes,"
"estimates," "predicts," "projects," "intend" or "continue" or the
negative of such terms or other comparable terminology, although
not all forward-looking statements contain these identifying words.
Forward-looking statements are subject to inherent risks and
uncertainties in predicting future results and conditions that
could cause the actual results to differ materially from those
projected in these forward-looking statements. These risks and
uncertainties are subject to the disclosures set forth in the "Risk
Factors" section of certain of our SEC filings. Forward-looking
statements are not guarantees of future performance, and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
ContactAshley
Oteroaotero@xbiotech.com512-386-2930
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Apr 2023 to Apr 2024